Experienced in Asthma

Dr. Jan H. Westerman

Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
Carolinas Medical Center
600 Hospital Dr, 
Monroe, NC 
Accepting New Patients
Offers Telehealth
Experienced in Asthma
Carolinas Medical Center
600 Hospital Dr, 
Monroe, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jan Westerman is a Pulmonary Medicine specialist and a Sleep Medicine provider in Monroe, North Carolina. Dr. Westerman is rated as an Experienced provider by MediFind in the treatment of Asthma. His top areas of expertise are Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), Drowsiness, Gastrostomy, and Endoscopy. Dr. Westerman is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Sleep Medicine
Intensive Care Medicine
Licenses
Critical Care Medicine in NC
Hospital Affiliations
Walker Baptist Medical Center
North Alabama Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

CAROLINAS MEDICAL CENTER
600 Hospital Dr, Monroe, NC 28112
Other Locations
CAROLINAS MEDICAL CENTER
201 E Grover St, Shelby, NC 28150
CAROLINAS MEDICAL CENTER
1000 Blythe Blvd, Charlotte, NC 28203
CAROLINAS MEDICAL CENTER
1350 S Kings Dr, Charlotte, NC 28207

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Enrollment Status: Completed
Publish Date: August 11, 2025
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Biological
Study Phase: Phase 2
A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
Enrollment Status: Terminated
Publish Date: October 08, 2024
Intervention Type: Drug
Study Drug: Niclosamide
Study Phase: Phase 2
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
Enrollment Status: Terminated
Publish Date: February 14, 2024
Intervention Type: Drug, Other
Study Drug: Deupirfenidone
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
Fitbit Sleep Apnea Alert Software Validation Study
Fitbit Sleep Apnea Alert Software Validation Study
Enrollment Status: Unknown
Publish Date: August 22, 2022
Intervention Type: Diagnostic test
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
Enrollment Status: Withdrawn
Publish Date: April 22, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

1 Total Publications

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Journal: Pulmonary pharmacology & therapeutics
Published: March 17, 2015
Similar Doctors
Patrick T. Kelly
Distinguished in Asthma
Dr. Patrick T. Kelly
Pulmonary Medicine
Distinguished in Asthma
Dr. Patrick T. Kelly
Pulmonary Medicine

Atrium Health Pulmonology & Sleep Medicine

1090 Northeast Gateway Court, Suite 201, 
Concord, NC 
 (28.2 miles away)
704-403-7770
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Kelly is a Pulmonary Medicine provider in Concord, North Carolina. Dr. Kelly is rated as a Distinguished provider by MediFind in the treatment of Asthma. His top areas of expertise are Lung Metastases, Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Asthma in Children. Dr. Kelly is currently accepting new patients.

Iyad H. Asaad
Advanced in Asthma
Dr. Iyad H. Asaad
Sleep Medicine | Intensive Care Medicine | Pulmonary Medicine
Advanced in Asthma
Dr. Iyad H. Asaad
Sleep Medicine | Intensive Care Medicine | Pulmonary Medicine

Atrium Health Pulmonology & Sleep Medicine

1090 Northeast Gateway Court, Suite 201, 
Concord, NC 
 (28.2 miles away)
704-403-7770
Experience:
30+ years
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Iyad Asaad is a Sleep Medicine specialist and an Intensive Care Medicine provider in Concord, North Carolina. Dr. Asaad has been practicing medicine for over 30 years and is rated as a Distinguished provider by MediFind in the treatment of Asthma. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Asthma in Children, Pleural Effusion, and Advanced Bronchoscopy. Dr. Asaad is currently accepting new patients.

Carl Smart
Distinguished in Asthma
Dr. Carl Smart
Pulmonary Medicine | Intensive Care Medicine
Distinguished in Asthma
Dr. Carl Smart
Pulmonary Medicine | Intensive Care Medicine

Novant Health Pulmonary Medicine South - Harrisburg

9550 Rocky River Road, Suite 100, 
Harrisburg, NC 
 (21.1 miles away)
704-316-3612
Experience:
38+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Carl Smart is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Harrisburg, North Carolina. Dr. Smart has been practicing medicine for over 38 years and is rated as a Distinguished provider by MediFind in the treatment of Asthma. His top areas of expertise are Sarcoidosis, Emphysema, Chronic Cough, and Bullae.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Westerman's expertise for a condition
ConditionClose
      View All 34 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile